Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qilinghuaxian Formula
- Development stage
- Phase 4
- Lead developer
- Ningbo No. 2 Hospital
- Administration
- Oral
01
Overview
Qilinghuaxian Formula is a Traditional Chinese Medicine (TCM) herbal composition developed by Ningbo No. 2 Hospital for the treatment of liver cirrhosis and fibrosis associated with chronic hepatitis B virus (HBV) infection. The formula is designed to exert anti-fibrotic effects by inhibiting the activation of hepatic stellate cells and reducing the accumulation of extracellular matrix in the liver. It is typically administered orally as a decoction or granule. Clinical research, including trial ChiCTR2200067068, investigates its potential to improve liver function and reverse histological damage in patients already receiving standard nucleos(t)ide analogue antiviral therapy.
- Other names
- Qiling Huaxian Formula麒苓化纤方
Beyond the preview
Go deeper on Qilinghuaxian Formula.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qilinghuaxian Formula.